Prof Thierry Andre speaks to ecancer about the results of the KEYNOTE-177 study that he presented at the ASCO 2020 virtual meeting.
He describes the background of the study, which evaluates the efficacy and safety of pembrolizumab versus chemotherapy for the treatment of patients with microsatellite-instability high/mismatch repair deficient metastatic (MSI-H/dMMR) colorectal cancer.
Prof Andre outlines the design and main results achieved in the trial, in which pembrolizumab was found to be superior to chemotherapy in terms of progression-free survival.
He states that these encouraging results should be the new standard of care for these patients, and the research group hope to publish the mature overall survival results next year.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.